enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Show more...
FAQ
enGene Therapeutics 今天的股價是多少?▼
S0N0.F 目前價格為 €6.04 EUR,過去 24 小時上漲了 +0%。在圖表上更密切關注 enGene Therapeutics 股價表現。
enGene Therapeutics 的股票代號是什麼?▼
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,enGene Therapeutics 的股票以代號 S0N0.F 進行交易。
enGene Therapeutics 下一次財報日期是什麼時候?▼
enGene Therapeutics 將於 June 12, 2026 公布下一次財報。
enGene Therapeutics 上一季度的財報如何?▼
S0N0.F 上一季度的財報為每股 -0.38 EUR,預估為 -0.48 EUR,帶來 +21.37% 的驚喜。下一季度的預估財報為每股 不適用 EUR。
enGene Therapeutics 有多少名員工?▼
截至 April 11, 2026,公司共有 56 名員工。
enGene Therapeutics 位於哪個產業?▼
enGene Therapeutics從事於Health Care產業。
enGene Therapeutics 何時完成拆股?▼
enGene Therapeutics 最近沒有進行任何拆股。
enGene Therapeutics 的總部在哪裡?▼
enGene Therapeutics 的總部位於 US 的 Montreal。